Site-of-Care Rules Getting Tougher
We’ve often written about the battle being fought around site-of-care. As we’ve suggested previously, it comes down to one word….. MONEY. Payers have been turning up
April 2, 2024
We’ve often written about the battle being fought around site-of-care. As we’ve suggested previously, it comes down to one word….. MONEY. Payers have been turning up
……………catching up on FDA approvals The FDA approved a new ORAL therapy, Fabhalta (iptacopan) from Novartis, the first oral monotherapy for the treatment of adults
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the press releases rarely
Did you hear it too? We are talking about hearing the melody to the old Queen song….. Anther One Bites the Dust! The one biting the
……..catching up on FDA approvals The FDA recently approved a new ORAL therapy, Truqap (capivasertib) from AstraZeneca Pharmaceuticals (AZ), for co-administration with Faslodex (fulvestrant) for adult
……..catching up on FDA approvals The FDA approved a new ORAL therapy, Ogsiveo (nirogacestat) to SpringWorks Therapeutics Inc., for adult patients with progressing desmoid tumors
Let’s see if we can get your attention…… “The market structure we have right now—three big PBMs dominating the market—will probably not be the one
……catching up on FDA approvals The FDA approved an oral therapy, Zurzuvae (zuranolone) from Biogen Inc./ Sage Therapeutics, Inc.) Zurzuvae is a neuroactive steroid gamma-aminobutyric
The FDA recently approved a new therapy, Omvoh (mirikizumab-mrkz) from Eli Lilly and Company, for the treatment of moderately to severely active ulcerative colitis (UC)
Mark Cuban can now be called a pharmacy trend setter. We’ve read about his cost-plus drugs model….. and it seems that Express Scripts (ESI) feels
